Hikma Pharmaceuticals (HIK) Stock Chart & Stock Price History → It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad) Free HIK Stock Alerts GBX 1,919 -31.13 (-1.60%) (As of 10:58 AM ET) Add Compare Share Share ChartStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability Hikma Pharmaceuticals Stock Price Performance5 Day Performance-2.88%1 Month Performance-3.76%3 Month Performance+3.42%6 Month Performance+9.56%Year-To-Date Performance+7.27%1 Year Performance+1.51% Receive HIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter Email Address Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE HIK Stock Chart for Monday, June, 10, 2024 HIK Chart by TradingView Hikma Pharmaceuticals Share Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization06/07/2024GBX 1,973GBX 1,950.13-1.16%GBX 1,982GBX 1,948.78238,187 shs£4.33 billion06/06/2024GBX 1,976GBX 1,973-0.15%GBX 1,976GBX 1,946216,710 shs£4.38 billion06/05/2024GBX 1,984GBX 1,976-0.40%GBX 2,008GBX 1,975245,993 shs£4.38 billion06/04/2024GBX 1,959GBX 1,984+1.28%GBX 1,988GBX 1,946277,846 shs£4.40 billion06/03/2024GBX 1,930GBX 1,959+1.50%GBX 1,970GBX 1,926254,763 shs£4.35 billion05/31/2024GBX 1,913GBX 1,930+0.89%GBX 1,936GBX 1,9041.66 million shs£4.28 billion Get the Latest News and Ratings for HIK and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 05/30/2024GBX 1,907GBX 1,913+0.31%GBX 1,923.99GBX 1,890321,465 shs£4.24 billion05/29/2024GBX 1,905GBX 1,907+0.10%GBX 1,927GBX 1,898286,675 shs£4.23 billion05/28/2024GBX 1,958GBX 1,905-2.71%GBX 1,981GBX 1,905253,040 shs£4.23 billion05/27/2024GBX 1,958GBX 1,958GBX 1,958GBX 1,937.42159,271 shs£4.34 billion05/24/2024GBX 1,959GBX 1,958-0.05%GBX 1,958GBX 1,937.42159,271 shs£4.34 billion05/23/2024GBX 1,939GBX 1,959+1.03%GBX 1,971GBX 1,940242,439 shs£4.35 billion05/22/2024GBX 1,932GBX 1,939+0.36%GBX 1,948GBX 1,904267,921 shs£4.30 billion05/21/2024GBX 1,973GBX 1,932-2.08%GBX 1,973.80GBX 1,926268,847 shs£4.29 billion05/20/2024GBX 1,978GBX 1,973-0.25%GBX 1,984GBX 1,962139,188 shs£4.38 billion05/17/2024GBX 1,983GBX 1,978-0.25%GBX 1,991GBX 1,971219,180 shs£4.39 billion05/16/2024GBX 2,028GBX 1,983-2.22%GBX 2,034GBX 1,979233,263 shs£4.40 billion05/15/2024GBX 2,002GBX 2,028+1.30%GBX 2,036GBX 2,010192,693 shs£4.50 billion05/14/2024GBX 2,012GBX 2,002-0.50%GBX 2,025.98GBX 1,994169,316 shs£4.44 billion05/13/2024GBX 1,994GBX 2,012+0.90%GBX 2,012GBX 1,969301,712 shs£4.46 billion05/10/2024GBX 1,981GBX 1,994+0.66%GBX 2,008GBX 1,979215,580 shs£4.42 billion05/09/2024GBX 1,973GBX 1,981+0.41%GBX 1,989GBX 1,966129,761 shs£4.40 billion05/08/2024GBX 1,956GBX 1,973+0.87%GBX 1,994GBX 1,959301,577 shs£4.38 billion05/07/2024GBX 1,960GBX 1,956-0.20%GBX 2,000GBX 1,956315,601 shs£4.34 billion05/06/2024GBX 1,960GBX 1,960GBX 1,977GBX 1,929299,373 shs£4.35 billion05/03/2024GBX 1,925GBX 1,960+1.82%GBX 1,977GBX 1,931289,757 shs£4.35 billion05/02/2024GBX 1,935GBX 1,925-0.52%GBX 1,942GBX 1,924296,323 shs£4.27 billion05/01/2024GBX 1,924GBX 1,935+0.57%GBX 1,935GBX 1,902230,275 shs£4.29 billion04/30/2024GBX 1,930GBX 1,924-0.31%GBX 1,947GBX 1,916365,276 shs£4.27 billion04/29/2024GBX 1,913GBX 1,930+0.89%GBX 1,930GBX 1,901344,066 shs£4.28 billion04/26/2024GBX 1,838.19GBX 1,913+4.07%GBX 1,920GBX 1,861366,712 shs£4.24 billion04/25/2024GBX 1,813GBX 1,838.19+1.39%GBX 1,882GBX 1,750701,467 shs£4.08 billion04/24/2024GBX 1,819GBX 1,813-0.33%GBX 1,838GBX 1,804334,463 shs£4.02 billion04/23/2024GBX 1,818GBX 1,819+0.06%GBX 1,832GBX 1,813295,948 shs£4.04 billion04/22/2024GBX 1,799GBX 1,818+1.06%GBX 1,830GBX 1,817358,300 shs£4.03 billion04/19/2024GBX 1,781.70GBX 1,799+0.97%GBX 1,807GBX 1,763303,984 shs£3.99 billion04/18/2024GBX 1,774GBX 1,781.70+0.43%GBX 1,801GBX 1,769785,976 shs£3.95 billion04/17/2024GBX 1,778.66GBX 1,774-0.26%GBX 1,792GBX 1,762270,399 shs£3.94 billion04/16/2024GBX 1,807GBX 1,778.66-1.57%GBX 1,800GBX 1,760647,208 shs£3.95 billion04/15/2024GBX 1,803GBX 1,807+0.22%GBX 1,814GBX 1,796220,669 shs£4.01 billionIt's time to ween off Chinese lithium! (Ad)As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promising companies to be watching closelyLearn how this American company is leading the lithium-ion revolution04/12/2024GBX 1,817GBX 1,803-0.77%GBX 1,835.57GBX 1,801195,915 shs£4.00 billion04/11/2024GBX 1,788GBX 1,817+1.62%GBX 1,818GBX 1,772310,167 shs£4.03 billion04/10/2024GBX 1,820.42GBX 1,788-1.78%GBX 1,822GBX 1,786250,755 shs£3.97 billion04/09/2024GBX 1,839GBX 1,820.42-1.01%GBX 1,841GBX 1,816256,984 shs£4.04 billion04/08/2024GBX 1,863GBX 1,839-1.29%GBX 1,857GBX 1,834181,638 shs£4.08 billion04/05/2024GBX 1,871GBX 1,863-0.43%GBX 1,864GBX 1,839299,850 shs£4.13 billion04/04/2024GBX 1,869GBX 1,871+0.11%GBX 1,879GBX 1,814360,285 shs£4.15 billion04/03/2024GBX 1,880GBX 1,869-0.59%GBX 1,871GBX 1,844287,011 shs£4.15 billion04/02/2024GBX 1,918.50GBX 1,880-2.01%GBX 1,906GBX 1,869433,897 shs£4.17 billion04/01/2024GBX 1,918.50GBX 1,918.50GBX 1,938GBX 1,887.50336,497 shs£4.26 billion03/29/2024GBX 1,918.50GBX 1,918.50GBX 1,938GBX 1,887.50336,497 shs£4.26 billion03/28/2024GBX 1,880.50GBX 1,918.50+2.02%GBX 1,937.50GBX 1,887.50504,023 shs£4.26 billion03/27/2024GBX 1,864.50GBX 1,880.50+0.86%GBX 1,880.50GBX 1,855238,140 shs£4.17 billion03/26/2024GBX 1,883GBX 1,864.50-0.98%GBX 1,898GBX 1,857.50431,871 shs£4.14 billion03/25/2024GBX 1,915.50GBX 1,883-1.70%GBX 1,916.50GBX 1,880.50876,861 shs£4.18 billion03/22/2024GBX 1,873.50GBX 1,915.50+2.24%GBX 1,919GBX 1,879.50426,140 shs£4.25 billion03/21/2024GBX 1,948GBX 1,873.50-3.82%GBX 1,936GBX 1,823.50871,057 shs£4.16 billion03/20/2024GBX 1,913GBX 1,948+1.83%GBX 1,963GBX 1,920604,120 shs£4.32 billion03/19/2024GBX 1,883GBX 1,913+1.59%GBX 1,913GBX 1,881791,937 shs£4.24 billion03/18/2024GBX 1,847GBX 1,883+1.95%GBX 1,885.50GBX 1,841.50348,802 shs£4.18 billion03/15/2024GBX 1,865GBX 1,847-0.97%GBX 1,866.50GBX 1,846.50975,131 shs£4.10 billion03/14/2024GBX 1,875GBX 1,865-0.53%GBX 1,881.50GBX 1,853.50310,005 shs£4.14 billion03/13/2024GBX 1,918GBX 1,875-2.24%GBX 1,932GBX 1,875744,285 shs£4.16 billion03/12/2024GBX 1,910GBX 1,918+0.42%GBX 1,931GBX 1,905.50252,951 shs£4.26 billion03/11/2024GBX 1,855.50GBX 1,910+2.94%GBX 1,910GBX 1,845679,040 shs£4.24 billion Related Companies: HUTCHMED Stock Price Chart Indivior Stock Price Chart Benchmark Stock Price Chart Alliance Pharma Stock Price Chart Allergy Therapeutics Stock Price Chart Beximco Pharmaceuticals Stock Price Chart Animalcare Group Stock Price Chart ECO Animal Health Group Stock Price Chart Celadon Pharmaceuticals Stock Price Chart Shield Therapeutics Stock Price Chart Receive HIK Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (LON:HIK) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredTrump convicted... now what?Unexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTime is Running Out - June 25th Deadline Approaching!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRIL...Paradigm Press | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.